Tempus AI's growth and partnerships make it an attractive investment. See why TEM stock is a solid Buy due to its ...

We recently compiled a list of the 10 AI News You Shouldn’t Miss. In this article, we are going to take a look at where ...

Piper Sandler analyst David Westenberg raised the firm’s price target on Tempus AI (TEM) to $70 from $40 and keeps a Neutral rating on ...

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc.

Fintel reports that on November 11, 2024, Stifel downgraded their outlook for Tempus AI (NasdaqGS:TEM) from Buy to Hold. ...

Stifel downgraded Tempus AI (TEM) to Hold from Buy with a price target of $65, up from $45. The stock is up 100% since its debut and Tempus ...

With Ambry Genetics in tow, Eric Lefkofsky's biotech startup hopes to accelerate its drive toward turning a profit.

CEO Eric Lefkofsky said the purchase of Ambry Genetics will expand Tempus’ testing portfolio and bring in a fast-growing ...

After a quarter century as a serial entrepreneur, Eric Lefkofsky wants his latest unicorn, health tech firm Tempus AI, to be the “enduring legacy” of his career. Here’s how he hopes it will ...

In addition, please check the fund’s top five holdings to know its best picks in 2024. Baron Discovery Fund highlighted ...

Aliso Viejo-based Ambrey Genetics Corp., Orange County’s third-largest medical diagnostics and testing company, has entered ...

Northwestern Medicine will be the first system to use Tempus' new algorithm to identify patients at risk for developing ...